Evidence map›Paper›PMID 31642371›Full record

ArticleJournal of neurotrauma2020

Chronic, Twice-Daily Dosing of an NK2 Receptor Agonist [Lys

Lesley Marson, Raymond Keast Piatt, Mary A Katofiasc, Carol Bobbitt, Karl B Thor

Open access · greenAbstract read
In one paragraph

Article in Journal of neurotrauma, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Recent Developments in On-Demand Voiding Therapies.The Journal of pharmacology and experimental therapeutics · 2024
    Review
  2. Article
  3. Review
  4. [LysJournal of basic and clinical physiology and pharmacology · 2023
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Lesley MarsonDignify Therapeutics LLC, Research Triangle Park, North Carolina.
Raymond Keast PiattDignify Therapeutics LLC, Research Triangle Park, North Carolina.
Mary A KatofiascDignify Therapeutics LLC, Research Triangle Park, North Carolina.
Carol BobbittDignify Therapeutics LLC, Research Triangle Park, North Carolina.
Karl B ThorDignify Therapeutics LLC, Research Triangle Park, North Carolina.
Dignify Therapeutics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute administration of [Lys5,Me,Leu9,Nle10]-NKA(4-10) (LMN-NKA) produces contractions of the detrusor and rectum with voiding in intact and acutely spinal cord injured (SCI) rats. In the current study, the ability of LMN-NKA (10 μg/kg or 100 μg/kg, subcutaneous [SC], twice a day [bid]) or vehicle to induce voiding and defecation in chronic SCI rats was examined across 30 days. After the last day of administration, voiding response rates and bladder pressure (BP) responses to LMN-NKA (intravenous [IV] and SC) were evaluated under anesthesia. In conscious rats, LMN-NKA (100 μg/kg) produced dose-dependent micturition within 5 min, with response rates >90%, and voiding efficiency >80% in males and >60% in females, which remained stable across the 1-month test period. Similarly, LMN-NKA administration rapidly induced defecation, which also remained stable. Under anesthesia, LMN-NKA increased BP, voiding efficiency, and voiding response rates, which reached 100% at 3 and 10 μg/kg IV in males and females, respectively. SC administration produced 100% response rates in males (30 μg/kg) but only 71% in females (100 μg/kg). Efficacy in rats chronically treated with LMN-NKA was similar to naïve and vehicle-treated rats, except for reduced voiding efficiency in chronically dosed female rats (100 μg/kg). No differences in bladder weights or collagen-to-smooth muscle ratios in histological sections were seen between the groups. Thus neither tolerance, nor sensitization, to LMN-NKA-induced micturition and defecation occurs with chronic administration in rats with chronic SCI. Efficacy was higher in male than in female rats.

Indexed as

AnimalsDefecationDose-Response Relationship, DrugDrug Administration ScheduleFemaleMalePeptide FragmentsRatsRats, Sprague-DawleyReceptors, Neurokinin-2Spinal Cord InjuriesThoracic VertebraeUrinationPeptide FragmentsReceptors, Neurokinin-2cystometrydefecationneurokinin 2 agonistspinal cord injuryvoiding

Identifiers

PMID31642371
PMCPMC7071061
OpenAlexW2981993054

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.